Expression of IAP family proteins and its clinical importance in breast cancer patients

Expression of IAP family proteins and its clinical importance in breast cancer patients

Inhibitor of apoptosis (IAP) family proteins is involved in mechanisms of resistance to apoptosis in various cancer cells. The aim of this study was to assess the expression of selected IAP proteins such as XIAP, cIAP-1, cIAP-2 and survivin in breast cancer patients and evaluates their relationship...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neoplasma 2015, Vol.62 (4), p.666-673
Hauptverfasser: Pluta, P, Jeziorski, A, Cebula-Obrzut, A Pluta B, Wierzbowska, A, Piekarski, J, Smolewski, P
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 673
container_issue 4
container_start_page 666
container_title Neoplasma
container_volume 62
creator Pluta, P
Jeziorski, A
Cebula-Obrzut, A Pluta B
Wierzbowska, A
Piekarski, J
Smolewski, P
description Inhibitor of apoptosis (IAP) family proteins is involved in mechanisms of resistance to apoptosis in various cancer cells. The aim of this study was to assess the expression of selected IAP proteins such as XIAP, cIAP-1, cIAP-2 and survivin in breast cancer patients and evaluates their relationship with the prognostic and predictive factors and their impact to overall survival (OS) and progression free survival (PFS). The study was conducted with the use of tissue samples prospectively collected from 92 previously untreated female breast cancer patients. The control encompassed 10 fibroadenoma patients. The expression of XIAP, cIAP-1, cIAP-2 and survivin was assessed using flow multicolor cytometry. XIAP expression was present in 99 % of the breast cancer patients (91/92) with the median expression 13.65% (range 1-66.8%). Expression of XIAP in breast cancer was significantly higher compared to the control group (p=0.006). Median expression of cIAP-1, cIAP-2 and survivin in the study group was 25.95% (range 0.8-83.7%), 16.7% (range 1-53.2%) and 4.6% (range 0-43%) respectively. In the rank Spearman test, strong correlations (p
doi_str_mv 10.4149/neo_2015_080
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1695175566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1695175566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-4a54ab25b5492de19773e22e24f981b4745c7d272a2edbc6c9c95b28c449cf733</originalsourceid><addsrcrecordid>eNpNkM9LwzAYhoMobszdPEuOHqwmX5KmOY7hj8FAD4rHkKYpRNq0Jhnof2_HpvhdXj54eHl5ELqk5JZTru6CGzQQKjSpyAmaU8aqgjMqT9GcEKgKKCsxQ8uUPsh0pSAA9BzNQCglVVnO0fv91xhdSn4IeGjxZvWCW9P77huPccjOh4RNaLDPCdvOB29Nh30_DjGbYB32AdfRmZSx3f8RjyZ7F3K6QGet6ZJbHnOB3h7uX9dPxfb5cbNebQvLQOWCG8FNDaIWXEHjqJKSOQAHvFUVrbnkwsoGJBhwTW1Lq6wSNVSWc2VbydgCXR96p7mfO5ey7n2yruvMpGaXNC2VoFKIspzQmwNq45BSdK0eo-9N_NaU6L1N_d_mhF8dm3d175o_-Ncd-wEQD3Ba</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695175566</pqid></control><display><type>article</type><title>Expression of IAP family proteins and its clinical importance in breast cancer patients</title><source>Alma/SFX Local Collection</source><creator>Pluta, P ; Jeziorski, A ; Cebula-Obrzut, A Pluta B ; Wierzbowska, A ; Piekarski, J ; Smolewski, P</creator><creatorcontrib>Pluta, P ; Jeziorski, A ; Cebula-Obrzut, A Pluta B ; Wierzbowska, A ; Piekarski, J ; Smolewski, P</creatorcontrib><description>Inhibitor of apoptosis (IAP) family proteins is involved in mechanisms of resistance to apoptosis in various cancer cells. The aim of this study was to assess the expression of selected IAP proteins such as XIAP, cIAP-1, cIAP-2 and survivin in breast cancer patients and evaluates their relationship with the prognostic and predictive factors and their impact to overall survival (OS) and progression free survival (PFS). The study was conducted with the use of tissue samples prospectively collected from 92 previously untreated female breast cancer patients. The control encompassed 10 fibroadenoma patients. The expression of XIAP, cIAP-1, cIAP-2 and survivin was assessed using flow multicolor cytometry. XIAP expression was present in 99 % of the breast cancer patients (91/92) with the median expression 13.65% (range 1-66.8%). Expression of XIAP in breast cancer was significantly higher compared to the control group (p=0.006). Median expression of cIAP-1, cIAP-2 and survivin in the study group was 25.95% (range 0.8-83.7%), 16.7% (range 1-53.2%) and 4.6% (range 0-43%) respectively. In the rank Spearman test, strong correlations (p&lt;0.001) were seen among the expressions of XIAP, cIAP-2 and survivin, in all combination. Additionally, week correlation between XIAP and cIAP-1 was observed (p=0.02). The median expression of XIAP and survivin was significantly higher in more advanced tumors (stages pT2/pT3 vs. pT1). The median PFS and OS in breast cancer group were 46.15 and 47.1 months respectively. No significant correlations were observed among expressions of IAP family proteins and survival. However, low expression of XIAP in breast cancer showed trend to longer PFS (p=0.08). XIAP, cIAP-1 cIAP-2 and survivin participate in antiapoptotic mechanisms in breast cancer and XIAP and survivin seem to have the most significant prognostic importance. Further studies are needed to establish more complete prognostic and predictive values of IAP family proteins in breast cancer patients.</description><identifier>ISSN: 0028-2685</identifier><identifier>ISSN: 1338-4317</identifier><identifier>EISSN: 1338-4317</identifier><identifier>DOI: 10.4149/neo_2015_080</identifier><identifier>PMID: 25997966</identifier><language>eng</language><publisher>Slovakia</publisher><ispartof>Neoplasma, 2015, Vol.62 (4), p.666-673</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-4a54ab25b5492de19773e22e24f981b4745c7d272a2edbc6c9c95b28c449cf733</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25997966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pluta, P</creatorcontrib><creatorcontrib>Jeziorski, A</creatorcontrib><creatorcontrib>Cebula-Obrzut, A Pluta B</creatorcontrib><creatorcontrib>Wierzbowska, A</creatorcontrib><creatorcontrib>Piekarski, J</creatorcontrib><creatorcontrib>Smolewski, P</creatorcontrib><title>Expression of IAP family proteins and its clinical importance in breast cancer patients</title><title>Neoplasma</title><addtitle>Neoplasma</addtitle><description>Inhibitor of apoptosis (IAP) family proteins is involved in mechanisms of resistance to apoptosis in various cancer cells. The aim of this study was to assess the expression of selected IAP proteins such as XIAP, cIAP-1, cIAP-2 and survivin in breast cancer patients and evaluates their relationship with the prognostic and predictive factors and their impact to overall survival (OS) and progression free survival (PFS). The study was conducted with the use of tissue samples prospectively collected from 92 previously untreated female breast cancer patients. The control encompassed 10 fibroadenoma patients. The expression of XIAP, cIAP-1, cIAP-2 and survivin was assessed using flow multicolor cytometry. XIAP expression was present in 99 % of the breast cancer patients (91/92) with the median expression 13.65% (range 1-66.8%). Expression of XIAP in breast cancer was significantly higher compared to the control group (p=0.006). Median expression of cIAP-1, cIAP-2 and survivin in the study group was 25.95% (range 0.8-83.7%), 16.7% (range 1-53.2%) and 4.6% (range 0-43%) respectively. In the rank Spearman test, strong correlations (p&lt;0.001) were seen among the expressions of XIAP, cIAP-2 and survivin, in all combination. Additionally, week correlation between XIAP and cIAP-1 was observed (p=0.02). The median expression of XIAP and survivin was significantly higher in more advanced tumors (stages pT2/pT3 vs. pT1). The median PFS and OS in breast cancer group were 46.15 and 47.1 months respectively. No significant correlations were observed among expressions of IAP family proteins and survival. However, low expression of XIAP in breast cancer showed trend to longer PFS (p=0.08). XIAP, cIAP-1 cIAP-2 and survivin participate in antiapoptotic mechanisms in breast cancer and XIAP and survivin seem to have the most significant prognostic importance. Further studies are needed to establish more complete prognostic and predictive values of IAP family proteins in breast cancer patients.</description><issn>0028-2685</issn><issn>1338-4317</issn><issn>1338-4317</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpNkM9LwzAYhoMobszdPEuOHqwmX5KmOY7hj8FAD4rHkKYpRNq0Jhnof2_HpvhdXj54eHl5ELqk5JZTru6CGzQQKjSpyAmaU8aqgjMqT9GcEKgKKCsxQ8uUPsh0pSAA9BzNQCglVVnO0fv91xhdSn4IeGjxZvWCW9P77huPccjOh4RNaLDPCdvOB29Nh30_DjGbYB32AdfRmZSx3f8RjyZ7F3K6QGet6ZJbHnOB3h7uX9dPxfb5cbNebQvLQOWCG8FNDaIWXEHjqJKSOQAHvFUVrbnkwsoGJBhwTW1Lq6wSNVSWc2VbydgCXR96p7mfO5ey7n2yruvMpGaXNC2VoFKIspzQmwNq45BSdK0eo-9N_NaU6L1N_d_mhF8dm3d175o_-Ncd-wEQD3Ba</recordid><startdate>2015</startdate><enddate>2015</enddate><creator>Pluta, P</creator><creator>Jeziorski, A</creator><creator>Cebula-Obrzut, A Pluta B</creator><creator>Wierzbowska, A</creator><creator>Piekarski, J</creator><creator>Smolewski, P</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2015</creationdate><title>Expression of IAP family proteins and its clinical importance in breast cancer patients</title><author>Pluta, P ; Jeziorski, A ; Cebula-Obrzut, A Pluta B ; Wierzbowska, A ; Piekarski, J ; Smolewski, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-4a54ab25b5492de19773e22e24f981b4745c7d272a2edbc6c9c95b28c449cf733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pluta, P</creatorcontrib><creatorcontrib>Jeziorski, A</creatorcontrib><creatorcontrib>Cebula-Obrzut, A Pluta B</creatorcontrib><creatorcontrib>Wierzbowska, A</creatorcontrib><creatorcontrib>Piekarski, J</creatorcontrib><creatorcontrib>Smolewski, P</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neoplasma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pluta, P</au><au>Jeziorski, A</au><au>Cebula-Obrzut, A Pluta B</au><au>Wierzbowska, A</au><au>Piekarski, J</au><au>Smolewski, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of IAP family proteins and its clinical importance in breast cancer patients</atitle><jtitle>Neoplasma</jtitle><addtitle>Neoplasma</addtitle><date>2015</date><risdate>2015</risdate><volume>62</volume><issue>4</issue><spage>666</spage><epage>673</epage><pages>666-673</pages><issn>0028-2685</issn><issn>1338-4317</issn><eissn>1338-4317</eissn><abstract>Inhibitor of apoptosis (IAP) family proteins is involved in mechanisms of resistance to apoptosis in various cancer cells. The aim of this study was to assess the expression of selected IAP proteins such as XIAP, cIAP-1, cIAP-2 and survivin in breast cancer patients and evaluates their relationship with the prognostic and predictive factors and their impact to overall survival (OS) and progression free survival (PFS). The study was conducted with the use of tissue samples prospectively collected from 92 previously untreated female breast cancer patients. The control encompassed 10 fibroadenoma patients. The expression of XIAP, cIAP-1, cIAP-2 and survivin was assessed using flow multicolor cytometry. XIAP expression was present in 99 % of the breast cancer patients (91/92) with the median expression 13.65% (range 1-66.8%). Expression of XIAP in breast cancer was significantly higher compared to the control group (p=0.006). Median expression of cIAP-1, cIAP-2 and survivin in the study group was 25.95% (range 0.8-83.7%), 16.7% (range 1-53.2%) and 4.6% (range 0-43%) respectively. In the rank Spearman test, strong correlations (p&lt;0.001) were seen among the expressions of XIAP, cIAP-2 and survivin, in all combination. Additionally, week correlation between XIAP and cIAP-1 was observed (p=0.02). The median expression of XIAP and survivin was significantly higher in more advanced tumors (stages pT2/pT3 vs. pT1). The median PFS and OS in breast cancer group were 46.15 and 47.1 months respectively. No significant correlations were observed among expressions of IAP family proteins and survival. However, low expression of XIAP in breast cancer showed trend to longer PFS (p=0.08). XIAP, cIAP-1 cIAP-2 and survivin participate in antiapoptotic mechanisms in breast cancer and XIAP and survivin seem to have the most significant prognostic importance. Further studies are needed to establish more complete prognostic and predictive values of IAP family proteins in breast cancer patients.</abstract><cop>Slovakia</cop><pmid>25997966</pmid><doi>10.4149/neo_2015_080</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-2685
ispartof Neoplasma, 2015, Vol.62 (4), p.666-673
issn 0028-2685
1338-4317
1338-4317
language eng
recordid cdi_proquest_miscellaneous_1695175566
source Alma/SFX Local Collection
title Expression of IAP family proteins and its clinical importance in breast cancer patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20IAP%20family%20proteins%20and%20its%20clinical%20importance%20in%20breast%20cancer%20patients&rft.jtitle=Neoplasma&rft.au=Pluta,%20P&rft.date=2015&rft.volume=62&rft.issue=4&rft.spage=666&rft.epage=673&rft.pages=666-673&rft.issn=0028-2685&rft.eissn=1338-4317&rft_id=info:doi/10.4149/neo_2015_080&rft_dat=%3Cproquest_cross%3E1695175566%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695175566&rft_id=info:pmid/25997966&rfr_iscdi=true